Search Results

You are looking at 201 - 210 of 868 items for :

  • Refine by Access: All x
Clear All
Full access

Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

considered whether EFS or OS provides a more clinically meaningful endpoint for improvement. After careful deliberation, the committee determined that avoiding relapses should take top priority for subgroups with expected EFS <75% to 80%, because (1) the

Full access

Real Personalized Medicine

James O. Armitage, William C. Wood, and Dan L. Longo

overall survival might eventually alter in favor of the group that received radiotherapy as a result of eventual death from lymphoma for some of the patients who experienced relapse, or may show an advantage for no radiotherapy because of the eventual

Full access

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy Gilligan, Daniel W. Lin, Rahul Aggarwal, David Chism, Nicholas Cost, Ithaar H. Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L. Hancock, Chad LaGrange, Ellis G. Levine, Thomas Longo, Will Lowrance, Bradley McGregor, Paul Monk, Joel Picus, Phillip Pierorazio, Soroush Rais-Bahrami, Philip Saylor, Kanishka Sircar, David C. Smith, Katherine Tzou, Daniel Vaena, David Vaughn, Kosj Yamoah, Jonathan Yamzon, Alyse Johnson-Chilla, Jennifer Keller, and Lenora A. Pluchino

, large-scale follow-up studies have historically used tumor relapse rather than tumor-specific survival to validate the relevance of pathologic parameters used for staging. 12 However, the association of hilar soft tissue and epididymal invasion with

Full access

“Coming Full Circle”: Reintroduction of Radiotherapy Delaying Chemotherapy Followed by Craniospinal Radiotherapy for Infants With Medulloblastoma

Nicholas G. Gottardo

craniospinal irradiation (CSI) was introduced in the 1950s to prevent the inevitable metastatic relapses throughout the central nervous system (CNS) that many patients sustained, cementing this modality as the backbone of medulloblastoma therapy. For children

Full access

Oncology Research Program

enzalutamide, a potent androgen receptor (AR) antagonist, in the treatment of patients with mantle cell lymphoma (MCL) that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Preclinical studies

Full access

Oncology Research Program

enzalutamide, a potent androgen receptor (AR) antagonist, in the treatment of patients with mantle cell lymphoma (MCL) that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Preclinical studies

Full access

Oncology Research Program

enzalutamide, a potent androgen receptor (AR) antagonist, in the treatment of patients with mantle cell lymphoma (MCL) that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Preclinical studies

Full access

JNCCN CE Offerings

: 6/10/14 CASE REPORT: An Unusual Presentation of Chronic Myelogenous Leukemia: A Review of Isolated Central Nervous System Relapse Expiration Date: 7/12/14 NCCN Guidelines® Insights: Breast Cancer, Version 3.2013 Expiration Date: 7/12/14 The

Full access

Multiple Myeloma

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr., Cristina Gasparetto, Carol Ann Huff, Adetola Kassim, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, and Furhan Yunus

and more effective treatment options. 2 , 3 MM is typically sensitive to a variety of cytotoxic drugs, both as initial treatment and as treatment of relapsed disease. Unfortunately, responses are transient, and MM is not considered curable with

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jorge Castillo, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Yubin Kang, Adetola Kassim, Michaela Liedtke, Ehsan Malek, Thomas Martin, Vishala T. Neppalli, James Omel, Noopur Raje, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Donna Weber, Joachim Yahalom, Rashmi Kumar, and Dorothy A. Shead

available. These NCCN Guidelines Insights focus on updates to the 2018 version of the NCCN Guidelines for MM, including those regarding therapy options for both newly diagnosed and relapsed/refractory (R/R) MM. There are several classes of agents used